Adverum Biotechnologies Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Adverum Biotechnologies's earnings have been declining at an average annual rate of -10.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 7.4% per year.
Belangrijke informatie
-10.5%
Groei van de winst
-0.8%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | 7.4% |
Rendement op eigen vermogen | -59.4% |
Nettomarge | n/a |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Feb 24We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
Sep 07Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10
Aug 11Adverum gains 13% to reach three-month high after Truist upgrade
Jul 07We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully
May 12We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Jul 17Adverum Biotechnologies: An Uncertain Path Forward
May 05Adverum Bio presents long-term data from ADVM-022 trial in wet AMD
May 03We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate
Apr 06Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
Feb 13Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy
Feb 02Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares
Jan 22Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market
Jan 11Adverum Biotechnologies announces new GMP gene therapy manufacturing facility
Jan 07How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?
Dec 31Opbrengsten en kosten
Hoe Adverum Biotechnologies geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 0 | -100 | 40 | 0 |
31 Mar 24 | 0 | -113 | 48 | 0 |
31 Dec 23 | 4 | -117 | 50 | 0 |
30 Sep 23 | 4 | -126 | 48 | 0 |
30 Jun 23 | 4 | -133 | 51 | 0 |
31 Mar 23 | 4 | -146 | 52 | 0 |
31 Dec 22 | 0 | -155 | 55 | 0 |
30 Sep 22 | 0 | -156 | 57 | 0 |
30 Jun 22 | 0 | -154 | 54 | 0 |
31 Mar 22 | 0 | -155 | 62 | 0 |
31 Dec 21 | 8 | -146 | 63 | 0 |
30 Sep 21 | 8 | -149 | 66 | 0 |
30 Jun 21 | 8 | -138 | 63 | 0 |
31 Mar 21 | 8 | -123 | 52 | 0 |
31 Dec 20 | 0 | -118 | 45 | 0 |
30 Sep 20 | 0 | -99 | 39 | 0 |
30 Jun 20 | 0 | -87 | 35 | 0 |
31 Mar 20 | 0 | -73 | 32 | 0 |
31 Dec 19 | 0 | -64 | 28 | 0 |
30 Sep 19 | 0 | -61 | 25 | 0 |
30 Jun 19 | 1 | -66 | 23 | 0 |
31 Mar 19 | 1 | -70 | 25 | 0 |
31 Dec 18 | 2 | -73 | 25 | 0 |
30 Sep 18 | 2 | -72 | 22 | 0 |
30 Jun 18 | 2 | -65 | 23 | 0 |
31 Mar 18 | 2 | -57 | 18 | 0 |
31 Dec 17 | 2 | -56 | 20 | 0 |
30 Sep 17 | 2 | -64 | 22 | 0 |
30 Jun 17 | 2 | -64 | 22 | 0 |
31 Mar 17 | 2 | -114 | 20 | 0 |
31 Dec 16 | 1 | -114 | 20 | 0 |
30 Sep 16 | 2 | -105 | 19 | 0 |
30 Jun 16 | 2 | -105 | 20 | 0 |
31 Mar 16 | 2 | -53 | 23 | 0 |
31 Dec 15 | 2 | -47 | 20 | 0 |
30 Sep 15 | 2 | -44 | 20 | 0 |
30 Jun 15 | 1 | -38 | 15 | 0 |
31 Mar 15 | 1 | -36 | 11 | 0 |
31 Dec 14 | 1 | -29 | 8 | 0 |
30 Sep 14 | 0 | -22 | 5 | 0 |
30 Jun 14 | 0 | -14 | 3 | 0 |
31 Mar 14 | 0 | -7 | 2 | 0 |
31 Dec 13 | 0 | -5 | 1 | 0 |
Kwaliteitswinsten: ADVM is currently unprofitable.
Groeiende winstmarge: ADVM is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ADVM is unprofitable, and losses have increased over the past 5 years at a rate of 10.5% per year.
Versnelling van de groei: Unable to compare ADVM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ADVM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: ADVM has a negative Return on Equity (-59.43%), as it is currently unprofitable.